We recently hosted 3 days of meetings. In addition to many new data points on critical new growth driver Xiidra (see last week’s note), mgt expects that the hemophilia business will grow nicely – even if there is stiff competition in the
inhibitor segment. Post the meetings, we believe SHPG remains well positioned to deliver ~15%+ EPS growth.
full note attached